Nine large pharmaceutical company decided to put information about drug trials at academic institutions in an attempt to explore treatment increased the chances of developing new drugs for psychiatric disorders such as schizophrenia.

The collaboration with Pfizer, AstraZeneca, Eli Lilly and Roche among others, the data from 67 tests over 11 approved drugs represent the largest database of clinical data in psychiatric research, but to gather the leaders of the project.

“We have learned a lot of brain research in the last 30 years … and it is expected that this knowledge was quickly and automatically translate new drugs,” says Kapur Shitij London Institute of Psychiatry at King’s College, the project director named new methods that will lead to new drugs for depression and schizophrenia or NEWMEDS.

“But he is here because the record was a bit disappointing.

Kapur said that the goal NEWMEDS for academic researchers and pharmaceutical companies learn from the past and find ways to speed up and simplify the process of obtaining drug candidates through clinical trials market.

“We hope that this move inversely to help the drought of new drugs in psychiatry,” he said.

One obstacle was the development of competition between rival companies, he said, a limited exchange of knowledge between different departments of the Academy.

Data Sharing

NEWMEDS statement pointed to three problem areas in drug discovery for psychiatric disorders, including lack of animal models, careful experiments show the lack of tools and tests in healthy volunteers that the first signs that do the drugs can and focus on clinical research methods, the almost remained unchanged for 50 years.

Pharmaceutical companies are not worried about exposure developing experimental drugs, but we share the information about drugs that have already received approval.

Eli Lilly, for example, sharing of data from experiments of its schizophrenia drug Risperdal, or risperidone, while AstraZeneca will open the archive to Seroquel or quetiapine.

“For 50 years we have rehearsed in the same way – with a standard placebo or active control for four to six weeks and using statistical methods,” said Jonathan Rabinowitz, Bar Ilan University in Israel, the data analysis NEWMEDS schizophrenia project out.

“By creating this series of large amounts of data … we can determine whether the evidence can be smaller, faster, and patients exposed to new drugs.”

Academic institutions that deal with the Swedish Karolinska Institute, Cambridge, UK University of Manchester, the Spanish National Research Council of the German National Institute of Mental Health.

Other pharmaceutical companies are units of Janssen Pharmaceutica Johnson & Johnson, Lundbeck, Novartis, Orion, serving private.